Moneycontrol PRO
dr reddys laboratories
Jump to
  • Dr Reddy's gains 2% on acquisition of Eton Pharma injectable product portfolio Jun 27, 2022 10:30 AM IST

    Dr Reddy's gains 2% on acquisition of Eton Pharma injectable product portfolio

    Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, plus contingent payments of up to USD 45 million.

  • Buy Dr. Reddy’s Laboratories; target of Rs 5550: Sharekhan Jun 23, 2022 11:43 AM IST

    Buy Dr. Reddy’s Laboratories; target of Rs 5550: Sharekhan

    Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated June 22, 2022.

  • Buy Dr Reddy's Laboratories; target of Rs 4960: ICICI Direct Jun 22, 2022 01:56 PM IST

    Buy Dr Reddy's Laboratories; target of Rs 4960: ICICI Direct

    ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4960 in its research report dated June 22, 2022.

  • Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher Jun 22, 2022 01:13 PM IST

    Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated June 22, 2022.

  • Dr Reddy's Laboratories launches Sorafenib tablets in UK market Jun 14, 2022 02:20 PM IST

    Dr Reddy's Laboratories launches Sorafenib tablets in UK market

    "We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.

  • Top 10 trading ideas from experts for next 3-4 weeks as bears maul the markets Jun 13, 2022 11:16 AM IST

    Top 10 trading ideas from experts for next 3-4 weeks as bears maul the markets

    After a short-term correction, Dr Reddy's Laboratories has formed higher bottom reversal formation. The stock is consistently taking support near the 50 and 20 day SMA (Rs 4,192, Rs 4,227)

  • Dr Reddy's arm inks pact with US-based Olema Pharmaceuticals Jun 10, 2022 07:43 AM IST

    Dr Reddy's arm inks pact with US-based Olema Pharmaceuticals

    Olema and Aurigene Discovery Technologies, a wholly-owned unit of Dr Reddy's Laboratories, have inked an exclusive global licence agreement in this regard.

  • Buy Dr. Reddy’s Laboratories; target of Rs 5261: KR Choksey May 24, 2022 01:46 PM IST

    Buy Dr. Reddy’s Laboratories; target of Rs 5261: KR Choksey

    KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5261 in its research report dated May 23, 2022.

  • Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher May 22, 2022 06:11 PM IST

    Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated May 20, 2022.

  • Buy Dr Reddy's Laboratories; target of Rs 4800: ICICI Direct May 21, 2022 08:49 PM IST

    Buy Dr Reddy's Laboratories; target of Rs 4800: ICICI Direct

    ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4800 in its research report dated May 20, 2022.

  • Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan May 21, 2022 08:30 PM IST

    Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan

    Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated May 19, 2022.

  • As Dr Reddy's rises after earnings, should you buy or sell stock? May 20, 2022 09:35 AM IST

    As Dr Reddy's rises after earnings, should you buy or sell stock?

    The company reported a 15 percent year-on-year rise in consolidated revenues from operations to Rs 5,437 crore for the March quarter.

  • Dr Reddys Labs Consolidated March 2022 Net Sales at Rs 5,474.90 crore, up 14.82% Y-o-Y May 19, 2022 04:00 PM IST

    Dr Reddys Labs Consolidated March 2022 Net Sales at Rs 5,474.90 crore, up 14.82% Y-o-Y

  • Dr Reddys Labs Standalone March 2022 Net Sales at Rs 3,668.70 crore, up 9.49% Y-o-Y May 19, 2022 04:00 PM IST

    Dr Reddys Labs Standalone March 2022 Net Sales at Rs 3,668.70 crore, up 9.49% Y-o-Y

  • Dr Reddy's inks pact with South Korean drug firm HK inno.N Corporation May 11, 2022 02:21 PM IST

    Dr Reddy's inks pact with South Korean drug firm HK inno.N Corporation

    Under the partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territories.

  • Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan Apr 12, 2022 10:25 PM IST

    Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan

    Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated April 12, 2022.

  • Trade Spotlight | What should investors do with Zee Entertainment, Sequent Scientific, Dr Reddys Laboratories on Friday? Mar 25, 2022 07:34 AM IST

    Trade Spotlight | What should investors do with Zee Entertainment, Sequent Scientific, Dr Reddys Laboratories on Friday?

    On Thursday, Zee Entertainment opened with a gap up and gained over 15 percent. In this month so far, it rallied over 34 percent. The important thing is, after a long time it succeeded to close above 200 & 50 day SMA (simple moving average).

  • Dr Reddy’s Laboratories gains 2% on selling of two anti-bacterial brands Feb 21, 2022 09:45 AM IST

    Dr Reddy’s Laboratories gains 2% on selling of two anti-bacterial brands

    The share touched a 52-week high of Rs 5,613.65 and a 52-week low of Rs 4,135.90 on 07 July, 2021 and 19 March, 2021.

  • Mankind Pharma to acquire two brands from Dr Reddy's Laboratories Feb 16, 2022 12:54 PM IST

    Mankind Pharma to acquire two brands from Dr Reddy's Laboratories

    As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both the products in India.

  • COVID-19 Vaccine: DGCI grants EUA for single dose Sputnik Light Feb 06, 2022 09:31 PM IST

    COVID-19 Vaccine: DGCI grants EUA for single dose Sputnik Light

    Tweeting the news out on February 6, the Health Minister said that this is India's ninth COVID-19 vaccine in the country.

  • Buy Dr Reddys Laboratories; target of Rs 5160: ICICI Direct Feb 01, 2022 05:54 PM IST

    Buy Dr Reddys Laboratories; target of Rs 5160: ICICI Direct

    ICICI Direct is bullish on Dr Reddys Laboratories has recommended buy rating on the stock with a target price of Rs 5160 in its research report dated January 29, 2021.

  • Dr Reddys Labs Consolidated December 2021 Net Sales at Rs 5,338.30 crore, up 8.02% Y-o-Y Feb 01, 2022 10:11 AM IST

    Dr Reddys Labs Consolidated December 2021 Net Sales at Rs 5,338.30 crore, up 8.02% Y-o-Y

  • Dr Reddys Labs Standalone December 2021 Net Sales at Rs 3,479.60 crore, up 2.09% Y-o-Y Feb 01, 2022 09:22 AM IST

    Dr Reddys Labs Standalone December 2021 Net Sales at Rs 3,479.60 crore, up 2.09% Y-o-Y

  • Trying to bring Sputnik M vaccine for adolescents to India: Dr Reddy's Jan 28, 2022 06:45 PM IST

    Trying to bring Sputnik M vaccine for adolescents to India: Dr Reddy's

    Addressing a press conference after announcing the company’s Q3 results, a senior executive of the drug maker said Phase 3 clinical trial data of Russia’s single dose COVID-19 vaccine Sputnik Light has been submitted to the regulator and is awaiting approval.

  • Dr Reddy’s, Strides Pharma shares rally on DCGI approval for COVID-19 drug Dec 29, 2021 10:13 AM IST

    Dr Reddy’s, Strides Pharma shares rally on DCGI approval for COVID-19 drug

    Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS‐CoV‐2

Sections
ISO 27001 - BSI Assurance Mark